A Selenium Containing Inhibitor for the Treatment of Hepatocellular Cancer
Hepatocellular carcinoma (HCC) is the third most deadly cancer in the world. New treatment strategies are desperately needed due to limited standard therapies. Activation of the Erk, Akt, and STAT3pathways is implicated in the prognosis of HCC. The Se,Se′-1,4-phenylenebis(1,2-ethanediyl) bisisoselen...
Main Authors: | Hephzibah Rani S. Tagaram, Dhimant Desai, Guangfu Li, Dai Liu, C. Bart Rountree, Kavitha Gowda, Arthur Berg, Shantu Amin, Kevin F. Staveley-O’Carroll, Eric T. Kimchi |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2016-03-01
|
Series: | Pharmaceuticals |
Subjects: | |
Online Access: | http://www.mdpi.com/1424-8247/9/2/18 |
Similar Items
-
Is Selenium a Potential Treatment for Cancer Metastasis?
by: Yu-Chi Chen, et al.
Published: (2013-04-01) -
Selenium Effects on the Trabecular Meshwork
by: Conley, Shannon Martha
Published: (2005) -
Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications
by: Nicola Personeni, et al.
Published: (2018-06-01) -
Toxicity of selenium, application of selenium in fertilizers, selenium treatment of seeds, and selenium in edible parts of plants
by: Garousi F.
Published: (2017-10-01) -
Absence of p53 gene expression in selenium molecular prevention of chemically Induced hepatocarcinogenesis in rats
by: Nasar Y Alwahaibi, et al.
Published: (2011-01-01)